Ryanodine receptor (RyR) antibodies are detected in about 50% of patients with myasthenia gravis who have a thymoma. The RyR is a calcium release channel involved in the mechanism of excitationcontraction coupling in striated muscle. In this study the severity of myasthenia gravis assessed by a five point disability score was compared between 12 patients with myasthenia gravis, a thymoma, and RyR antibodies and 10 patients with myasthenia gravis and a thymoma but without such antibodies. Symptoms of myasthenia gravis were significantly more severe in patients with RyR antibodies. The mean (SD) disability scores were 3-7(0.5) in patients with antibodies and 2.7(0.9) in those without at peak of illness, (p = 0.01) and 3-4(1-4) v 1.6(0.7) at the end of an average observation period of five years (p = 0.002). The number of deaths due to myasthenia gravis was five of 12 RyR antibody positive patients, and none of 10 RyR antibody negative patients (p = 0.04). RyR antibody levels correlated positively with severity of myasthenia gravis. The presence of circulating RyR antibodies seems to be associated with a severe form of thymoma associated myasthenia gravis.
CITATION STYLE
Mygland, A., Aarli, J. A., Matre, R., & Gilhus, N. E. (1994). Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 57(7), 843–846. https://doi.org/10.1136/jnnp.57.7.843
Mendeley helps you to discover research relevant for your work.